Gabapentin and Oxcarbazepine for Pediatric Chronic Neuropathic Pain

This study is looking at how well two medications, Gabapentin and Oxcarbazepine, work to reduce chronic neuropathic pain (pain from nerve damage) in children and teenagers. Participants aged 8 to 18 with chronic neuropathic pain will be randomly assigned to receive either Gabapentin or Oxcarbazepine. Neither you nor the study team will know which medication you are receiving (this is called "blinded"). The study will measure if your pain significantly decreases from your starting pain level. The goal is to see how often these treatments successfully reduce pain. The study aims to enroll 60 participants, but its current recruitment status is unclear.

Study design
This is a randomized, double-blind study comparing two treatments, Gabapentin and Oxcarbazepine, in children and adolescents. It plans to enroll 60 participants.
What's involved
Pain scores will be measured at the start of the study, and then at 2, 4, 6, and 8 weeks after starting the medication.
Compensation
Not stated in the trial record.
Follow-up
Pain levels will be monitored for 8 weeks after starting the assigned medication.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02219373

Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study

Not Yet Recruiting
PHASE3Ages 8–18InterventionalTreatment
Boston Children's Hospital
~60 participants
Updated 2026-03-05 on ClinicalTrials.gov
What's tested:GabapentinOxcarbazepinePlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
As a primary outcome, success will be defined by clinically and statistically significant within subject reductions in pain scores
Measured over 0 (baseline), 2, 4, 6, 8 weeks (post-assignment of intervention)
Pediatric Chronic Neuropathic Pain
1 sites across 1 states
Massachusetts1
  • Monique Ribeiro, MD · PRINCIPAL_INVESTIGATOR · Boston Children's Hospital

Opens a ready-to-send draft in your own email app — review before sending.

  • As a primary outcome, success will be defined by clinically and statistically significant within subject reductions in pain scores0 (baseline), 2, 4, 6, 8 weeks (post-assignment of intervention)

    1. 2 point reduction in average daily pain scores 2. 30% reduction relative to baseline 3. Global overall impression of strong benefit.